Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Persistence and effectiveness of upadacitinib and TNFi for rheumatoid arthritis using pooled data from Canadian and Swiss registries.

Rheumatology (Oxford, England)·2026

Same author

Golimumab for the Treatment of Rheumatoid Arthritis: A Narrative Review of Pivotal Randomized Trials and Real-World Studies.

Rheumatology and therapy·2026

Same author

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update.

Annals of the rheumatic diseases·2026

Same author

Sleep improvement in patients with rheumatoid arthritis treated with upadacitinib in real-world practice: results from the SLEERA study.

Arthritis research & therapy·2026

Same author

Identification of individuals at high risk of developing rheumatoid arthritis: a balanced random forest model in a cohort of 1544 first-degree relatives.

RMD open·2025

Same author

Risk factors for recurrence or relapse after a first episode of adult IgA vasculitis: A multicenter retrospective study.

Journal of the American Academy of Dermatology·2025

Same journal

Public Health Response to Clade Ib Mpox with Multiple Exposures in Congregate Living Settings - New Hampshire, February 2025.

NEJM evidence·2026

Same journal

Berberine-Ursodeoxycholate - Bringing Traditional Chinese Medicine to Our World.

NEJM evidence·2026

Same journal

Outbreak of Legionnaires' Disease Associated with Cooling Tower Systems in Central Harlem.

NEJM evidence·2026

Same journal

Immunotherapy for Fertility in Autoimmune Premature Ovarian Insufficiency.

NEJM evidence·2026

Same journal

A Randomized Trial of Interval Likelihood Ratios for Clinical Decision-Making.

NEJM evidence·2026

Same journal

Evidence for Evidence-Based Medicine - A Call for Some Theory and a New Problem.

NEJM evidence·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Secukinumab for Giant Cell Arteritis.

John H Stone¹, Nils Venhoff², Frank Buttgereit^3,4

¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

|June 3, 2026

Summary

This summary is machine-generated.

Secukinumab did not significantly improve sustained remission rates in giant cell arteritis (GCA) patients compared to placebo when used with a 26-week glucocorticoid taper. Further research is needed to explore secukinumab

More Related Videos

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Published on: January 31, 2020

Related Experiment Videos

Last Updated: Jun 4, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Published on: January 31, 2020

Area of Science:

Rheumatology
Immunology
Clinical Trials

Background:

Giant cell arteritis (GCA) is typically treated with glucocorticoids (GCs), but relapses and toxicity are common.
Secukinumab, an interleukin-17A inhibitor, is being investigated as an additional therapy for GCA to mitigate these issues.

Purpose of the Study:

To evaluate the efficacy of secukinumab as an add-on therapy for patients with new-onset or relapsing giant cell arteritis.
To compare sustained remission rates at 52 weeks between secukinumab and placebo groups with different glucocorticoid tapering schedules.

Main Methods:

The GCAptAIN trial was a phase 3, randomized, double-blind, placebo-controlled study involving patients with GCA.
Patients received either secukinumab (300 mg or 150 mg) or placebo, with a 26-week GC taper for secukinumab groups and a 52-week taper for the placebo group.
The primary outcome was sustained remission at week 52 in the SEC-300 versus placebo groups.

Main Results:

Sustained remission at week 52 was achieved by 25.6% of patients on SEC-300 versus 16.9% on placebo (P=0.09).
The SEC-150 group showed a sustained remission rate of 19.4% versus 17.7% for placebo (marginal difference).
Adverse events were frequent across all groups; serious adverse events and serious infections were also assessed.

Conclusions:

Secukinumab, with a 26-week GC taper, did not lead to a statistically significant difference in sustained remission at week 52 compared to placebo with a 52-week GC taper in GCA patients.
The study did not meet its primary endpoint, suggesting secukinumab may not be effective as an add-on therapy under these specific trial conditions.